dailyai.report

£150 million will fund a new AI hub in central London over the next decade. Boehringer Ingelheim aims to accelerate drug discovery and clinical development through this expansion. The investment scales their local technical footprint. This move signals a long-term commitment to integrating machine learning into pharmaceutical R&D pipelines for UK researchers.